莫德纳2025年Q4财报超预期，股价单日大涨7.58%

Core Viewpoint - Moderna's stock price surged 7.58% to $43.15 after the release of its Q4 and full-year 2025 financial results, reaching a new high for the year [1] Financial Performance - Q4 revenue was $678 million, exceeding market expectations of $625.1 million, despite a 30% year-over-year decline; strong sales of COVID-19 vaccines in the U.S. alleviated concerns about ongoing revenue shrinkage [2] - Full-year operating expenses for 2025 were revised down to $5-5.2 billion, a reduction of $200 million from previous guidance; year-end cash reserves are expected to reach $8.1 billion, up from earlier estimates of $6.5-7 billion, enhancing financial resilience [3] - Q4 loss per share was $2.11, an improvement from a loss of $2.91 in the same period last year, indicating a contraction in losses [3] Business Developments - The RSV vaccine mRESVIA has been approved in 40 countries; although the flu vaccine mRNA-1010 was rejected by the FDA, the company plans to reapply with additional data; the personalized cancer vaccine mRNA-4157, in collaboration with Merck, has entered Phase III clinical trials, indicating progress in a diversified pipeline [4] - Management emphasized a shift of resources towards high-margin beauty and health businesses, optimizing the brand portfolio [4] Market Performance - On the same day, the Nasdaq index rose by 0.42%, and the biotechnology sector increased by 1.85%, reflecting positive industry sentiment [5] Capital and Technical Aspects - Low valuation (negative TTM P/E) and high volatility attracted short-term capital inflows, with a daily price fluctuation of 8.90% and trading volume at 1.6 times the recent average [6] Future Outlook - The setback in flu vaccine approval may delay the 2028 breakeven target; the company remains reliant on COVID-19 vaccine revenue, which constitutes the majority of Q4 2025 revenue, and the commercial success of new pipelines is yet to be observed [7]